Previous 10 | Next 10 |
Presentations to be webcast on www.exelixis.com Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will be presenting at the following investor conferences in February: BIO CEO & Inves...
– Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy – Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the cl...
Exelixis (NASDAQ: EXEL ) perks up 1% premarket on light volume on the heels of results from an open-label Phase 1/2 clinical trial, CheckMate 040 , evaluating the combination of Cabometyx (cabozantinib) and Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab), with or withou...
– Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium – Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1/2 clinical trial results from the combination of cabozantinib (CABOMETYX...
Exelixis ( EXEL ) has been a stock which has seen more or less stagnation even as the underlying news flow has been reasonably good. The company certainly looks promising and in my last review of the investment thesis in May of 2018, I noted that it was time to excel. Shares have been stag...
Investors looking for an undervalued biotechnology stock that provides long-term profitability should consider adding Exelixis (NASDAQ: EXEL) to their portfolios. Exelixis is a profitable company thanks to the success of its lead cancer drug, Cabometyx, which treats various fo...
"Some of the biggest cases of mistaken identity are among intellectuals who have trouble remembering that they are not God. ” ― Thomas Sowell Today, we revisit mid-cap oncology concern Exelixis ( EXEL ) . Several events have occurred since we last looked at this name five w...
If you were invested in the stock market in 2019, there's a good chance you're smiling from ear to ear. The benchmark S&P 500 , which has historically returned 7% per year, inclusive of dividend reinvestment and when adjusting for inflation, gained a whopping 29% in 2019. The big question ...
Exelixis, Inc. (EXEL) 38th Annual JPMorgan Healthcare Conference Call January 14, 2020 7:30 P.M. ET Company Participants Michael Morrissey - President and Chief Executive Officer Conference Call Participants Eric Joseph - JPMorgan Presentation Eric Joseph I’m E...
The following slide deck was published by Exelixis, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...